The move marks Italy’s Angelini Pharma’s entry into the U.S. market.

Catalyst continues to actively enroll patients in the SUMMIT study, an open-label five-year follow-up study designed to evaluate the long-term clinical safety profile of AGAMREE, including potential ...

A research team from Sungkyunkwan University and Kyungpook National University has developed a non-precious ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Catalyst believes that the non-GAAP financial measures presented in this press release provide investors and prospective investors with an alternative method for assessing Catalyst's operating results ...

A visualization of the exterior of the Catalyst building when completed from a bird’s-eye view. Renderings courtesy of Koelbel and Company. A new healthcare innovation hub opening in Omaha in early ...

Italian drugmaker Angelini Pharma SpA agreed to buy Catalyst Pharmaceuticals Inc. for $4.1 billion as it looks to grow in the US and build a footprint in rare diseases.